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Word of Welcome
On behalf of the EHA Board and the Scientific Program Committee we are pleased to introduce to you
this year’s Abstract Program. The richness of the program is a testament to EHA’s spirit: unity through
diversity.
The Scientific Program Committee has compiled an exciting program of Simultaneous Oral and
Poster Sessions from close to 2500 submitted abstracts representing all fields of hematology. For the
second year, a number of presenters will have the opportunity to pitch their abstract. These Poster
pitches are an exciting opportunity to promote basic science and research, and to invite delegates to the
poster walks. 
The six Best Abstracts will be presented during the Presidential Symposium on Friday afternoon. This
will be a session not to miss. During this plenary session EHA is also awarding, for the first time, the
best abstracts by trainees in four categories in basic and clinical hematology research. These awardees
and the travel grant winners can be found on the next page. YoungEHA are the future of hematology!
The late breaking abstract submission is an integral part of the scientific program. The late breaking
submission is intended for abstracts with “hot” data that were not available by the time of the regular
submission deadline. Only few abstracts, with the most exciting results are selected for a presentation
in the Late Breaking Oral Session on Sunday morning. 
A selection of abstracts will be presented during the regular Poster Walks. The Poster Session con-
sists of two parts: the Poster Walk and dedicated Poster Browsing Time. This setup guarantees suffi-
cient time for discussion of the important research presented, so look out for the Poster Walk
Moderators in their red baseball caps! There will also be E-posters available on the E-poster screens,
for which a specific time is allocated during the Poster Browsing Time at the end of each Walk. The
Simultaneous Oral Sessions are spread over three days (Friday to Sunday) providing you with ample
opportunity to attend a number of these important sessions.
All posters can be viewed on the E-poster screens from Friday morning to Saturday evening. All the
abstracts are also available on the EHA Learning Center, for which you have complimentary access after
the congress: learningcenter.ehaweb.org.
On behalf of the EHA Board, the committees and all the people involved in this year’s EHA Congress,
we thank you for coming to Madrid and wish you a great meeting.
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Travel Grant Winners
For this Congress 140 travel grants have been awarded to junior members of EHA, based on the mean score
of their abstracts.
EHA congratulates the following persons with their travel grants:
Agrawal M, Germany
Anagnostou T, USA
Arriazu E, Spain
Barcia Duran JG, USA
Beekman R, Spain
Bhoi S, Sweden
Binder M, USA
Birgisdóttir AM, Iceland
Blunt M, United Kingdom
Botthof J, United Kingdom
Bouillon AS, Belgium
Bröckelmann P, Germany
Buffiere A, France
Burney C, United Kingdom
Cabal-Hierro L, USA
Caraffini V, Austria
Casado Izquierdo P, United
Kingdom
Cerchione C, Italy
Chaudhry G, India
Chitre S, United Kingdom
Cleyrat C, USA
De Bie J, Belgium
de la Morena-Barrio ME,
Spain
De Paepe K, United Kingdom
De Rosa G, Italy
Di Marcantonio D, USA
Dinmohamed A, the
Netherlands
Dominguez Rodriguez M,
Spain
Duran-Ferrer M, Spain
Eisfeld AK, USA
Escriba Garcia L, Spain
Eskelund C, Denmark
Fancello L, Belgium
Farina F, Italy
Fattizzo B, Italy
Fernandez MC, Spain
Ferrero S, Italy
Figueroa R, Spain
Flasinski M, Germany
Gabelli M, Italy
Ganuza Fernandez M, USA
García Ramírez P, Spain
Geelen I, the Netherlands
Giannoni L, Italy
Gugliotta G, Italy
Hansen J, Denmark
Hasibeder A, Germany
Healey M, United Kingdom
Hermetet F, France
Herrmann O, Germany
Hu B, USA
Iskander D, United Kingdom
Jaafar S, United Kingdom
Jentzsch M, Germany
Jetani H, Germany
Kampen K, Belgium
Karamitros D, United
Kingdom
Kardosova M, Czech
Republic
Karjalainen R, Finland
Karsa M, Australia
Kim JC, Republic of Korea
Kim T, Canada
Koning MT, the Netherlands
Larrea de Orte E, Spain
Li X, China
Lippert L, Germany
Machnicki MM, Poland
Maekawa T, Japan
Manier S, France
Mannion N, United Kingdom
Manta L, Germany
Marchesini M, Italy
McKerrell T, United Kingdom
McPherson S, United
Kingdom
Medrano Domínguez M,
Spain
Meyer-Pannwitt V, Germany
Milani P, Italy
Miller K, USA
Mitchell RJ, United Kingdom
Mora B, Italy
Morales Hernandez A, USA
Morita K, Japan
Nadeu F, Spain
Nasso D, Italy
Norfo R, United Kingdom
O’Byrne S, United Kingdom
Okasha D, Egypt
Ordonez R, Spain
Papaioannou D, USA
Passaro D, United Kingdom
Pawlyn C, United Kingdom
Pei X, China
Peric Z, Croatia
Plevova K, Czech Republic
Pozzo F, Italy
Prassek VV, Germany
Pugliese N, Italy
Rencz F, Hungary
Ribeiro D, Portugal
Rotolo A, United Kingdom
Saeed BRM, Germany
Sala E, Italy
Schmidt L, Austria
Schwartzman O, Israel
Seyfried F, Germany
Short N, USA
Smith J, United Kingdom
Song Y, China
Stamatopoulos B, Belgium
Stege C, the Netherlands
Stieglitz E, USA
Sud A, United Kingdom
Suksangpleng T, Thailand
Sulima S, Belgium
Suzuki K, Japan
Svaton M, Czech Republic
Sverrisdottir IS, Iceland
Talati C, USA
Theis F, Germany
Thivakaran A, Germany
Thompson P, USA
Thorsteinsdottir S, Iceland
Tissino E, Italy
Toda J, Japan
Unnikrishnan A, Australia
Uras I, Austria
Van de Wyngaert Z, France
Van den Bergh M, USA
van Dooijeweert B, the
Netherlands
van Straaten S, the
Netherlands
Vermaat J, the Netherlands
Versluis J, the Netherlands
Vinas l, Spain
Vinchi F, Germany
Viswanathan GK, India
Wannez A, Belgium
Weigl A, Germany
Wiggers C, the Netherlands
Zaninetti C, Italy
CLINICAL TRAINEE AWARD
K C Pawlyn, United Kingdom
MD-PHD AWARD
K O Schwartzman, Israel
PHD RESEARCH STUDENT
AWARD
K JG Barcia Duran, USA
POSTDOCTORAL RESEARCH
TRAINEE AWARD
K F Vinchi, Italy
Travel Grant supported by Giuseppe Bigi Association
Salvatore D, Italy
YoungEHA Best Abstract Awards
One of the primary missions of the European Hematology Association is to support young hematology clinicians and
researchers. This year we are proud to announce the launching of the YoungEHA Best Abstract Awards. These will be
awarded to the highest ranking abstracts in the following four categories: Clinicians or medical students training for
a PhD degree, PhD research students, postdoctoral fellows and clinical hematology trainees. We are honored that
these outstanding YoungEHA trainees will be presenting during the EHA congress – they are the future of Hematology!
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OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH
OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE
IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH
DEFERRED ASCT (PADIMAC)
K. Yong1,*, R. De Tute2, D. De-Silva1, E. Phillips3, N. Counsell3, J. Cavenagh4,
C. Roddie1, R. Owen2, M. Streetly5, S. Schey6, M. Koh7, J. Crowe8, M. Quinn9,
S. D’Sa10, A. Virchis11, G. Cook12, C. Crawley13, G. Pratt14, M. Cook15,
J. Ashcroft16, R. Benjamin6, T. Adedayo3, N. Braganca3, J. Lyons-Lewis17,
P. Smith3, L. Clifton-Hadley3, N. Rabin17, R. Popat1
1UCL Cancer Institute, University College London, London, 2Haematology,
Leeds Teaching Hospital NHS Trust, Leeds, 3CRUK and UCL Clinical Trials
Centre, University College London, 4Haematology, St Bartholomew’s Hospital,
5Haematology, Guy’s Hospital, 6Haematology, King’s College Hospital,
7Haematology, St George’s Hospital, London, 8Haematology, Royal United
Hospital, Bath, 9Haematology, Belfast Hospital, Belfast, 10Haematology, Mt
Vernon Cancer Centre, Herts, 11Haematology, Barnet and Chase Farm Hos-
pital, London, 12Haematology, St James’s University Hospital, Leeds, 13Haema-
tology, Addenbrookes Hospital, Cambridge, 14Haematology, Heart of England
NHS Foundation Trust, 15Haematology, Queen Elizabeth Hospital, Birmingham,
16Haematology, Mid Yorks NHS Trust, Wakefield, 17Haematology, University
College London Hospital, London, United Kingdom
Background: The role of autologous stem cell transplantation (ASCT) as first
line therapy for newly diagnosed (ND) patients with multiple myeloma (MM)
remains under evaluation given the deep responses to novel induction regi-
mens. Outcomes for those not proceeding to ASCT following induction remain
unclear, likely to be influenced by genetic risk and response depth. This study
was designed to evaluate a stratified approach to ASCT, investigating if patients
in CR/VGPR to induction may safely be assigned to delayed ASCT.
Aims: This single arm phase 2 clinical trial conducted at 13 UK sites aimed to
determine the progression free survival (PFS) for patients who achieved
≥VGPR to induction therapy with no further treatment. Here we report the pri-
mary endpoint, PFS at 2 years in the patients not proceeding to ASCT, and the
influence of MRD status on PFS.
Methods: NDMM patients eligible for ASCT received PAD (bortezomib
1.3mg/m2 IV or SC days 1, 4, 8, 11; doxorubicin 9mg/m2 days 1-4, dexam-
ethasone 40mg days 1-4 (and days 8-11 and 15-18 for cycle 1 only)) for 4-6
cycles. Those achieving <PR were off protocol; all others had PBSCH followed
by restaging including MRD assessment on bone marrow using multi-parame-
ter flow cytometry. Those in PR were stratified to ASCT (no maintenance)
whereas those achieving ≥VGPR stopped treatment. Responses were
assessed at 100 days post PBSCH (including MRD), and at monthly intervals
for up to 2 years. High risk disease was defined by the presence of one or
more adverse FISH lesions (t(4;14), t(14;16), t(14;20), del(17p13), +1q21).
Results: Between April 2011 and January 2014 153 patients were enrolled
(median age 55, range 28-71 years), 139 (91%) received 4-6 cycles of PAD.
The majority (88.2%) received SC bortezomib, 18 (11.8%) received at least 1
cycle IV. FISH data was available for 132 patients, 89 (67.4%) patients were
standard and 43 (32.6%) adverse risk. 51 (33.6%) patients were ISS I, 67
(44.1%) ISS II and 34 (22.4%) ISS III. The overall response rate to PAD was
82.4% (≥VGPR: 41.2%). Responses were similar irrespective of ISS or genetic
risk (standard: ≥VGPR 37.5%, PR 40.9%, adverse: ≥VGPR 53.5%, PR 34.9%).
Post-PBSCH, 63 (41.2%) patients achieved ≥VGPR, and 44 (28.8%) patients
achieved PR of whom 36 proceeded to ASCT. After a median follow-up of 45.4
months from registration, median overall PFS was 22.5m (95% CI: 18.1-25.3).
For those who achieved ≥VGPR, median PFS from PBSCH was 8.9m (95% CI:
4.6-13.3) and 25.7m (95% CI: 13.7-37.6) for MRD+ (N=25) and MRD- (N=16)
patients at D100 post-PBSCH respectively, 2y-PFS 28.0% (95% CI: 10.4-45.6)
and 56.3% (95% CI: 32.0-80.6) respectively. PR patients proceeding to ASCT
had a median PFS of 17.2m (95% CI: 14.2-20.2) and 23.1m (95% CI: 16.8-
29.4) for those who were MRD+ (N=20) and MRD- (N=7) at D100 respectively,
2y-PFS 15.0% (95% CI: 0-30.7) and 42.9% (95% CI: 6.2-79.6) respectively.
Summary/Conclusions: This is the first study to report outcomes of patients
stratified to ASCT by depth of response. The overall PFS for the study is shorter
than other published trials, most likely due to the inferior outcome for MRD+
patients not proceeding to ASCT. The median PFS for ≥VGPR patients who
are MRD- and stopped therapy was similar to that in PR patients achieving
MRD- status post-ASCT. The PFS for ASCT was relatively short, reflecting
selection of those only achieving PR. Response rate alone is not sufficient to
identify patients who would benefit from ASCT and use of MRD to stratify treat-
ment is now being investigated.
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